Zai Lab to Announce Second Quarter 2022 Financial Results on August 9, 2022
19 juil. 2022 07h38 HE
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab Announces Inclusion of its Ordinary Shares in Two Stock Connect Programs
17 juil. 2022 20h00 HE
|
Zai Lab Limited
Inclusion of Zai Lab shares in Shanghai-Hong Kong Stock Connect is effective today Zai Lab has been dual-primary listed on Nasdaq and the Hong Kong Stock Exchange, and its shares included in the...
Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis
13 juil. 2022 07h30 HE
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., July 13, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab Announces Primary Listing on the Main Board of The Stock Exchange of Hong Kong Limited
27 juin 2022 00h00 HE
|
Zai Lab Limited
– First company to Convert from Secondary to Primary Listing Status in Hong Kong – Our dual Primary Listing on the Nasdaq and Hong Kong Stock Exchange provides greater access for investors ...
Zai Lab Announces Breakthrough Therapy Designations Granted for Repotrectinib in China
10 juin 2022 07h30 HE
|
Zai Lab Limited
-- Breakthrough Therapy Designations granted for ROS1-positive non-small cell lung cancer (NSCLC) patients pretreated with one prior line of ROS1 tyrosine kinase inhibitor (TKI) with or without prior...
Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
03 juin 2022 08h00 HE
|
Zai Lab Limited
Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% SHANGHAI and...
Zai Lab to Present New PRIME Subgroup Analysis for Niraparib in Ovarian Cancer at 2022 ASCO Annual Conference
31 mai 2022 08h00 HE
|
Zai Lab Limited
Presentation features a new subgroup analysis of the Phase 3 PRIME study exploring the efficacy of niraparib maintenance therapy for patients in China with advanced ovarian cancer based on their...
Zai Lab Announces Upcoming Presentations at June Investor Conferences
24 mai 2022 07h30 HE
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab Announces Change to Virtual 2022 Annual General Meeting of Shareholders to be Held on June 22, 2022
20 mai 2022 16h01 HE
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab Announces First Quarter 2022 Financial Results and Corporate Updates
10 mai 2022 16h01 HE
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...